Verrica Pharmaceuticals Inc. Marketable Securities, Unrealized Gain (Loss)
Verrica Pharmaceuticals Inc. (VRCA) reported Marketable Securities, Unrealized Gain (Loss) of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Income Statement
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2024-02-29
- Verrica Pharmaceuticals Inc. marketable securities, unrealized gain (loss) for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. marketable securities, unrealized gain (loss) for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. marketable securities, unrealized gain (loss) for the quarter ending 2023-06-30 was $0.00.
- Verrica Pharmaceuticals Inc. marketable securities, unrealized gain (loss) for the quarter ending 2023-03-31 was $0.00.
- Verrica Pharmaceuticals Inc. marketable securities, unrealized gain (loss) for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Verrica Pharmaceuticals Inc. marketable securities, unrealized gain (loss) for fiscal 2022 was $29.00K.
- Verrica Pharmaceuticals Inc. marketable securities, unrealized gain (loss) for fiscal 2021 was -$30.00K.
- Verrica Pharmaceuticals Inc. marketable securities, unrealized gain (loss) for fiscal 2020 was -$19.00K, a 151.35% decline from fiscal 2019.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $29.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $29.00K derived: sum of 3 quarters · filed 2024-02-29 | $64.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $29.00K derived: sum of 2 quarters · filed 2024-02-29 | $64.00K derived: sum of 3 quarters · filed 2024-02-29 | $62.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $64.00K derived: sum of 2 quarters · filed 2024-02-29 | $62.00K derived: sum of 3 quarters · filed 2024-02-29 | $29.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $33.00K derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | -$27.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$35.00K 10-Q · filed 2023-08-08 | -$62.00K derived: sum of 3 quarters · filed 2023-08-08 | -$63.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$33.00K 10-Q · filed 2023-05-09 | -$60.00K derived: sum of 2 quarters · filed 2023-05-09 | -$61.00K derived: sum of 3 quarters · filed 2023-05-09 | -$65.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$28.00K derived: sum of 2 quarters · filed 2023-03-06 | -$32.00K derived: sum of 3 quarters · filed 2023-03-06 | -$30.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$5.00K derived: sum of 2 quarters · filed 2022-11-07 | -$3.00K 10-Q · filed 2022-11-07 | -$8.00K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$2.00K 10-Q · filed 2022-08-11 | -$7.00K derived: sum of 3 quarters · filed 2022-08-11 | -$33.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $2.00K 10-Q · filed 2022-05-09 | -$3.00K derived: sum of 2 quarters · filed 2022-05-09 | -$29.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | -$31.00K derived: sum of 2 quarters · filed 2022-03-02 | -$19.00K 10-K · filed 2022-03-02 | |
| 2020-09-30 | -$26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$14.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $12.00K 10-Q · filed 2021-08-10 | |||
| 2019-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | -$18.00K derived: sum of 2 quarters · filed 2021-03-17 | $37.00K 10-K · filed 2021-03-17 | |
| 2019-09-30 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $44.00K 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $55.00K 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | -$17.00K 10-K · filed 2020-03-13 | ||
| 2018-09-30 | -$7.00K 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |